Victor Manuel Navas-Lopez
Overview
Explore the profile of Victor Manuel Navas-Lopez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ledder O, Dolinger M, Dubinsky M, Stein R, Vellanki S, Buckuk R, et al.
Inflamm Bowel Dis
. 2024 Jun;
31(2):425-431.
PMID: 38828483
Background: Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety of...
12.
Cohen S, Rolandsdotter H, Kolho K, Turner D, Tzivinikos C, Bramuzzo M, et al.
Paediatr Drugs
. 2024 May;
26(5):609-617.
PMID: 38780740
Background And Objectives: Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety...
13.
Rodriguez-Belvis M, Palomino L, Pujol-Muncunill G, Martin-Masot R, Medina Benitez E, Fernandez-Lorenzo A, et al.
Eur J Pediatr
. 2024 May;
183(8):3417-3430.
PMID: 38771373
Conclusion: The SEGHNP versions of IMPACT-III and IMPACT-III-P are valid and reliable instruments for Spanish p-IBD families. What Is Known: • IMPACT-III and parent-proxy IMPACT-III (IMPACT-III-P) are useful questionnaires for...
14.
Ramos-Cozar S, Martin-Masot R, Rodriguez-Gallego B, Rubio L, Cabanillas-Moruno J, Navas-Lopez V
Gastroenterol Hepatol
. 2024 May;
47(9):502194.
PMID: 38714272
Introduction: Inflammatory bowel disease (IBD) is a chronic disorder that can lead to periods of work-related temporary disability (TD), which may result in the need for permanent disability. The objective...
15.
Pujol-Muncunill G, Navas-Lopez V, Ledder O, Cohen S, Lekar M, Turner D, et al.
Eur J Pediatr
. 2024 May;
183(8):3253-3262.
PMID: 38700692
Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and...
16.
Salvador-Martin S, Rubbini G, Vellosillo P, Zapata-Cobo P, Velasco M, Palomino L, et al.
Biomed Pharmacother
. 2024 Feb;
173:116299.
PMID: 38401525
Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes...
17.
Sigall Boneh R, Westoby C, Oseran I, Sarbagili-Shabat C, Albenberg L, Lionetti P, et al.
Inflamm Bowel Dis
. 2023 Nov;
30(10):1888-1902.
PMID: 37978895
Dietary therapy is increasingly recognized for the management of Crohn's disease (CD) over recent years, including the use of exclusive enteral nutrition (EEN) as first-line therapy for pediatric CD according...
18.
Herrador-Lopez M, Martin-Masot R, Navas-Lopez V
Nutrients
. 2023 Oct;
15(19).
PMID: 37836478
(1) Background: Ulcerative colitis (UC) is a chronic colon inflammation caused by genetic and environmental factors, including diet. This systematic review and meta-analysis aims to assess the impact of diet...
19.
Zapata-Cobo P, Salvador-Matin S, Velasco M, Palomino L, Clemente S, Segarra O, et al.
Pharmacol Res
. 2023 Sep;
196:106938.
PMID: 37748560
No abstract available.
20.
Godoy-Molina E, Vazquez-Pareja M, Perez-Frias J, Navas-Lopez V, Nunez-Cuadros E
An Pediatr (Engl Ed)
. 2023 Sep;
99(4):271-275.
PMID: 37735026
No abstract available.